Clinical trials: Plaque Psoriasis.
Psoriasis
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects (18 years of age and older) with chronic moderate or worse plaque psoriasis who have had an inadequate response to…
- Trial name
- NCT00336973
- Testing
- efalizumab
- Volunteers
- 73 people
- Sponsor
- Genentech, Inc.
Psoriasis
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease…
- Trial name
- NCT02295865
- Testing
- JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg
- Where
- 13 sites in United States, Poland
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
There is clearly a need for further data on the efficacy of biologic agents in the treatment of nail and scalp psoriasis, especially in the routine clinical setting.
- Trial name
- NCT01202565
- Where
- 73 sites in Czechia, Estonia and 6 more
- Volunteers
- 506 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
- Trial name
- NCT00691964
- Testing
- ABT-874, etanercept
- Where
- 35 sites in United States
- Volunteers
- 347 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis Vulgaris
A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris
The purpose of this study is to evaluate the anti-psoriatic effect of LEO 27989 ointment and calcipotriol plus LEO 27989 ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
- Trial name
- NCT01297166
- Testing
- LEO 27989 ointment, Calcipotriol plus LEO 27989 ointment, Calcipotriol ointment
- Where
- France
- Volunteers
- 25 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
The objective of the study is to evaluate the safety and efficacy of a topical lotion.
- Trial name
- NCT02462070
- Testing
- IDP-118 Lotion, IDP-118 Vehicle Lotion
- Where
- 16 sites in United States
- Volunteers
- 203 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- EVERLAST-B (NCT07290569)
- Testing
- ORKA-001
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 160 people
- Sponsor
- Oruka Therapeutics, Inc.
Psoriasis
Study in Patients With Mild to Moderate Psoriasis
This was a randomized, double blind,fixed dose, placebo controlled, parallel-group pilot study to obtain data on size and variance of treatment effects in subjects with mild to moderate Psoriasis.
- Trial name
- AH-PSR-01 (NCT01451346)
- Testing
- B. Infantis 35624
- Where
- Ireland
- Volunteers
- 47 people
- Sponsor
- Alimentary Health Ltd
Psoriasis Vulgaris
A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic…
- Trial name
- NCT03331835
- Testing
- Brodalumab, Fumaric acid esters
- Where
- 30 sites in Germany
- Volunteers
- 210 people
- Sponsor
- LEO Pharma
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis
A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis
The purpose of the study is to evaluate the efficacy and safety of AC-201 tablets compared with placebo in subjects with moderate-to-severe plaque psoriasis
- Trial name
- NCT06972888
- Testing
- AC-201
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Accro Bioscience (Suzhou) Limited
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
- Trial name
- MATURE (NCT03589885)
- Testing
- Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Plaque-type Psoriasis
Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
Low doses of topically administered vitamin D analogs have been shown to have an anti-psoriatic effect without the risk of hypercalcemia.
- Trial name
- NCT00625326
- Testing
- COL-121, 50 µg/g Calcipotriene Ointment
- Where
- 20 sites in United States
- Volunteers
- 321 people
- Sponsor
- Deltanoid Pharmaceuticals
Palmoplantar Psoriasis
A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Palmoplantar psoriasis (PPPsO) is a type of psoriasis that affects the palms of hands and soles of the feet. It can cause red, thick, scaly patches, and it is often associated with pain and itching.
- Trial name
- NCT07752108
- Testing
- Zasocitinib
- Volunteers
- 40 people
- Sponsor
- Takeda
Scalp Psoriasis
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
- Trial name
- NCT03897088
- Testing
- PART 2: Double-blind Active Treatment Extension
- Where
- 25 sites in United States, Australia
- Volunteers
- 231 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis.
- Trial name
- reSURFACE 2 (NCT01729754)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg, Etanercept 50 mg
- Volunteers
- 1,090 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in…
- Trial name
- NCT06477237
- Testing
- HB0017 Q4W, HB0017 Q8W
- Where
- 44 sites in China
- Volunteers
- 408 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
- Trial name
- PROTOSTAR (NCT03451851)
- Testing
- Guselkumab, Etanercept
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque…
- Trial name
- NCT02564042
- Testing
- GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
- Where
- 46 sites in United States, Canada and 1 more
- Volunteers
- 227 people
- Sponsor
- GlaxoSmithKline
Chronic Plaque Psoriasis
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic…
- Trial name
- NCT00493324
- Testing
- alefacept, polyvalent pneumococcal vaccine
- Where
- 7 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Astellas Pharma Inc